Across TCGA pan-cancer cohorts, COL11A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COL11A2 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher COL11A2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated COL11A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, LIHC, and SCLC are the cancer types where COL11A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.968	0.823	.004	30	view →
LIHC	DFS	Median	All	0.267	0.548	.030	9	view →
SCLC	DFS	Median	All	0.690	0.244	.027	6	view →
SKCM	DFS	Median	II,III,IV	0.760	0.527	.004	4	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: COL11A2 tumor-vs-normal RNA expression · all COL11A2 data types